Verapamil attenuates the malignant treatment course in recurrent status epilepticus

被引：33

作者：

Schmitt, Friedhelm C. ^{[1
,2
]}

Dehnicke, Christoph ^{[2
]}

Merschhemke, Martin ^{[2
]}

Meencke, Heinz-Joachim ^{[2
]}

机构：

[1] Otto Von Guericke Univ, Univ Hosp Neurol, D-39120 Magdeburg, Germany

[2] Humboldt Univ, Teaching Hosp, Epilepsy Ctr Berlin Brandenburg, Ev Krankenhaus Konigin Elisabeth Herzberg, Berlin, Germany

来源：

EPILEPSY & BEHAVIOR | 2010年 / 17卷 / 04期

关键词：

Malignant; Multidrug transporter; Pharmacoresistance; P-glycoprotein; Refractory; Recurrent; Status epilepticus; Verapamil; REFRACTORY STATUS EPILEPTICUS; ANTIEPILEPTIC DRUGS; P-GLYCOPROTEIN; EPILEPSY; ANTAGONISTS; MODULATION; BLOCKERS; SEIZURE;

D O I：

10.1016/j.yebeh.2010.01.166

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

In the scenario of refractory status epilepticus, the recommended approach of intensive care treatment is limited with respect to the available pharmacodynamic variability and its impeding, severe side effects. Alternative treatment options are therefore urgently needed. In the case described, a patient with nonlesional frontal lobe epilepsy had a high-frequency series of tonic seizures, which evolved into a malignant form of status epilepticus. Co-administration of verapamil, a potent multidrug transporter inhibitor, was followed by significant reduction in seizure frequency. We discuss the putative role of verapamil and the specific risk factors for this malignant treatment course. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：565 / 568

页数：4

共 25 条

[11] Potential role of drug transporters in the pathogenesis of medically intractable epilepsy [J].

Kwan, P ;

Brodie, TJ .

EPILEPSIA, 2005, 46 (02) :224-235

[12] Mechanisms of drug resistance in status epilepticus [J].

Loescher, Wolfgang .

EPILEPSIA, 2007, 48 :74-77

[13] Several major antiepileptic drugs are substrates for human P-glycoprotein [J].

Luna-Tortos, Carlos ;

Fedrowitz, Maren ;

Loescher, Wolfgang .

NEUROPHARMACOLOGY, 2008, 55 (08) :1364-1375

[14]

Luszczki JJ, 2007, PHARMACOL REP, V59, P672

[15]

MAJKOWSKI J, 2005, ANTIEPILEPTIC DRUGS, P139

[16] Modulation of P-glycoprotein at the blood-brain barrier: Opportunities to improve central nervous system pharmacotherapy [J].

Miller, David S. ;

Bauer, Bjoern ;

Hartz, Anika M. S. .

PHARMACOLOGICAL REVIEWS, 2008, 60 (02) :196-209

[17] A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease - The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial [J].

Pepine, CJ ;

Handberg, EM ;

Cooper-Dehoff, RM ;

Marks, RG ;

Kowey, P ;

Messerli, FH ;

Mancia, G ;

Cangiano, JL ;

Garcia-Barreto, D ;

Keltai, M ;

Erdine, S ;

Bristol, HA ;

Kolb, HR ;

Bakris, GL ;

Cohen, JD ;

Parmley, WW .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (21) :2805-2816

[18] The neurobiology of antiepileptic drugs [J].

Rogawski, MA ;

Löscher, W .

NATURE REVIEWS NEUROSCIENCE, 2004, 5 (07) :553-564

[19]

ROPPER AH, 2004, NEUROLOGICAL NEUROSU, P314

[20] Refractory status epilepticus - Effect of treatment aggressiveness on prognosis [J].

Rossetti, AO ;

Logroscino, G ;

Bromfield, EB .

ARCHIVES OF NEUROLOGY, 2005, 62 (11) :1698-1702

← 1 2 3 →